LYNCH-SYNDROME RELATED GYNECOLOGIC PATHOLOGY

MARIA LUISA CARCANGIU M.D.
1913- Michigan pathologist Aldred Scott Warthin studied the family history of his seamstress who first developed colon cancer, and later died of endometrial cancer.

She confided to him that one day she would die of cancer of the colon or of the female organs, "because everyone in my family died of these diseases."

Her pedigree became known as “Family G” and illustrated a long line of colonic and endometrial cancer.
## Colorectal and LS-Associated Cancers in Family G

<table>
<thead>
<tr>
<th>Site</th>
<th>No. of Cases</th>
<th>Age at Diagnosis, Mean (SD) [Range]†</th>
<th>Generations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectum</td>
<td>56</td>
<td>55 (16) [23-93]</td>
<td>II, III, IV, V</td>
</tr>
<tr>
<td>Endometrium</td>
<td>16</td>
<td>53 (12) [39-78]</td>
<td>II, III, IV, V</td>
</tr>
<tr>
<td>Stomach</td>
<td>8</td>
<td>62 (12) [44-76]</td>
<td>II, III, IV, V</td>
</tr>
<tr>
<td>Brain</td>
<td>4</td>
<td>44 (16) [23-59]</td>
<td>III, IV, V</td>
</tr>
<tr>
<td>Ovary</td>
<td>1</td>
<td>44</td>
<td>V</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><em><em>85</em>†</em>*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Includes 74 individuals; 8 were diagnosed with multiple (2-5) primary cancers.
†Actual age is given for cancer of the ovary.
MEMBERS OF FAMILY G WITH MULTIPLE COLORECTAL AND LS-ASSOCIATED CANCERS

<table>
<thead>
<tr>
<th>Generation</th>
<th>Branch</th>
<th>Sex</th>
<th>Cancer Sites</th>
<th>Ages at Diagnosis, y</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>B</td>
<td>Female</td>
<td>Endometrium, colon (NOS)</td>
<td>75, 79</td>
</tr>
<tr>
<td>IV</td>
<td>B</td>
<td>Female</td>
<td>Colon (NOS), sigmoid</td>
<td>65, 75</td>
</tr>
<tr>
<td>V</td>
<td>D</td>
<td>Male</td>
<td>Ascending colon, sigmoid</td>
<td>41, 51</td>
</tr>
<tr>
<td>III</td>
<td>G</td>
<td>Female</td>
<td>Endometrium, cecum, sigmoid, stomach*</td>
<td>50, 60, 70, 72, 76</td>
</tr>
<tr>
<td>IV</td>
<td>I</td>
<td>Male</td>
<td>Cecum, descending colon</td>
<td>26, 27</td>
</tr>
<tr>
<td>III</td>
<td>I</td>
<td>Female</td>
<td>Endometrium, cecum</td>
<td>55, 57</td>
</tr>
<tr>
<td>IV</td>
<td>I</td>
<td>Female</td>
<td>Colon (NOS), colon (NOS)</td>
<td>43, 67</td>
</tr>
<tr>
<td>V</td>
<td>I</td>
<td>Female</td>
<td>Cecum, rectum</td>
<td>28, 45</td>
</tr>
</tbody>
</table>

Abbreviation: NOS, not otherwise specified.
*Cancer of the sigmoid was diagnosed twice at ages 60 and 72 years.*
CARDINAL CLINICAL FEATURES OF LYNCH SYNDROME (HNPCC)

- Dominant inheritance; high penetrance
- Main cancers: colorectal, endometrial
- Other frequent cancers: gastric, ovarian
- Other infrequent cancers: small bowel, pancreas, ureter, renal pelvis, biliary tract, brain tumors in the Turcot syndrome variant of HNPCC, cutaneous stigmata (sebaceous adenomas, sebaceous carcinomas, and multiple keratoacanthomas) in the Muir–Torre syndrome variant of HNPCC
Before molecular genetic diagnostics came of age in the 1990s, a comprehensive family history was the only basis on which familial risk of colorectal cancer could be estimated.
- **Amsterdam Criteria (Classic ICP-HNPCC Criteria), 1990 †**
  Clinical HNPCC identification requires at least three relatives with CRC plus the following:
  1) One affected patient is a first-degree relative of the other two
  2) Two or more successive generations affected
  3) One or more affected relative received CRC diagnosis at age <50
  4) Familial adenomatous polyposis excluded
  5) Tumours verified by pathological examination

- **Amsterdam II Criteria (revised ICG-HNPCC Criteria) 1998 ‡**
  Clinical HNPCC identification requires three or more relatives with HNPCC associated cancer (CRC, or cancer of the endometrium, small bowel, ureter, or renal pelvis) plus all of the following:
  1) One affected patient is a first-degree relative of the other two
  2) Two or more successive generations affected
  3) One or more affected relative received diagnosed at age <50 y
  4) Familial adenomatous polyposis excluded in any cases of CRC
  5) Tumours verified by pathological examination

- **Bethesda Guidelines 1996 #**
  Guidelines for identification of patients with colorectal tumors who should undergo testing for microsatellite instability:
  1) Cancer in families that meet the Amsterdam Criteria
  2) Two HNPCC-related tumors, including synchronous and metachronous CRC or associated extracolonic cancer (endometrium, ovarian, gastric, hepatobiliary, or small bowel cancer or transitional-cell carcinoma of the renal pelvis or ureter)
  3) CRC and a first degree relative with CRC or HNPCC-related extracolonic cancer or a colorectal adenoma; one of the cancers diagnosed at the age < 40 y, and the adenoma diagnosed at the age < 40 y
  4) CRC or endometrium carcinoma < 50 y
  5) Right-sided CRC with an undifferentiated pattern (solid, cribriform) on histopathology < 45 y
  6) Signet ring cell type CRC < 50 y
  7) Adenoma < 40 y

* CRC = colorectal cancer; HNPCC = hereditary nonpolyposis colorectal cancer; ICG = International Collaborative Group on familial colorectal cancer; † Amsterdam, Netherlands; ‡ revised Amsterdam, Netherlands; # Bethesda, Maryland
Contribution of Gene Mutations to LS Families

- **MSH2** ~ 60%
- **MLH1** ~ 30%
- **MSH6** (rare)
- **PMS2** (rare)
- **PMS1** (rare)
- **MLH1** ~ 30%
ENDOMETRIAL CARCINOMA IN WOMEN WITH LYNCH SYNDROME
PREVALENCE OF GERM-LINE (INHERITED) DNA MISMATCH REPAIR GENE MUTATION IN THE GENERAL POPULATION:

1:2000-1:600

ATTRIBUTABLE TO MMR MUTATIONS:

~ 1-3% OF ALL ENDOMETRIAL CANCERS

~ 5% OF ENDOMETRIAL CANCERS IN WOMEN <55 YEARS OF AGE

Frequency of germline DNA MMR

- Mutations among unselected patients with EC has been found to be 1.8% to 2.3%
- In patients younger than 50 years, the incidence of mutation is increased up to 9%
LIFETIME RISK OF CANCER REPORTED IN FAMILIES WITH AN IDENTIFIED MISMATCH REPAIR MUTATION

- Colorectal cancer (men): 28–75%
- Colorectal cancer (women): 24–52%
- **Endometrial cancer:** 27–71% [2.3%]
- **Ovarian cancer:** 3.6 –13% [1.8%]
- Gastric cancer: 2–13%
- Urinary tract cancer: 1–12%
- Brain tumour: 1–4%
- Bile duct/gallbladder cancer: 2%
- Small-bowel cancer: 4–7%

## Endometrial Cancer Risk Assessment

Hendriks et al. 2006

<table>
<thead>
<tr>
<th>MMR Gene</th>
<th>Cumulative Endometrial Carcinoma Risk (at Age 70)</th>
<th>Mean Age of Diagnosis of Endometrial Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>MLH1</td>
<td>27%</td>
<td>48 years</td>
</tr>
<tr>
<td>MSH2</td>
<td>40%</td>
<td>49 years</td>
</tr>
<tr>
<td>MSH6</td>
<td>71%</td>
<td>54 years</td>
</tr>
</tbody>
</table>

General population: 2.3%
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.


117 WOMEN WITH DUAL PRIMARY CANCERS FROM 223 AMSTERDAM FAMILIES

<table>
<thead>
<tr>
<th>First primary</th>
<th>n.</th>
<th>Median age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon</td>
<td>49 (49%)</td>
<td>40ys</td>
</tr>
<tr>
<td>Endometrium</td>
<td>46 (45.5%)</td>
<td>45ys</td>
</tr>
<tr>
<td>Ovary</td>
<td>6 (5.9%)</td>
<td>39.5ys</td>
</tr>
</tbody>
</table>

16 cases diagnosed simultaneously
CRC/endometrial ca. : 11 cases
CRC/ovarian ca. : 4 cases
CRC/endometrial/ovarian ca. : 1 case
Bethesda Criteria.

1. Individuals with two HNPCC-related cancers, including synchronous and metachronous colorectal cancers or associated extracolonic cancers (endometrial, ovarian, gastric, hepatobiliary, small bowel cancer or transitional cell carcinoma of the renal pelvis or ureter)

2. Individuals with colorectal cancer and a first degree relative with colorectal cancer and/or HNPCC-related extracolonic cancer and/or colorectal adenoma; one of the cancers diagnosed at age <45 y, and the adenoma diagnosed at age <40 y

3. Individuals with colorectal cancer or endometrial cancer diagnosed at age <45 y

4. Individuals with right-sided colorectal cancer with an undifferentiated pattern on histopathology diagnosed at age <45 y

5. Individuals with signet-ring-cell-type colorectal cancer diagnosed at age <45 y

6. Individuals with adenomas diagnosed at age <40 y
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.

Walsh CS, Blum A, Walts A, Alsabeh R, Tran H, Koeffler HP, Karlan BY.
72 eligible patients:

50 with early-onset endometrial cancer

22 with synchronous endometrial and ovarian primary cancers

molecular findings consistent with LS:

6/50 (12%)

3/22 (14%)

Walsh CS, 2010
Women With Synchronous Primary Cancers of the Endometrium and Ovary: Do They Have Lynch Syndrome?

Pamela T. Soliman, Russell R. Broaddus, Kathleen M. Schmeler, Molly S. Daniels, Delia Gonzalez, Brian M. Slomovitz, David M. Gershenson, Karen H. Lu
102 women with synchronous endometrial and ovarian cancers (1989-2004)
Median age 50 years

- 59 patients had tumor blocks available for analysis

- 7% of women met either clinical or molecular criteria for Lynch syndrome. All of these women had a prior history or a first-degree relative with an HNPCC-associated cancer
45 patients with a median age at diagnosis of 53 years.

Of a total of 134 samples analyzed, only three samples (3.3%) were MSI-H
Carcinoma of the Lower Uterine Segment: A Newly Described Association With Lynch Syndrome
Westin, S. N. et al.
Journal of Clinical Oncology, 26, 2008:5965-5971

- 35 (3.5%) of 1,009 women with endometrial cancer had endometrial carcinoma of the LUS.

- LUS patients were younger, had higher stage tumors, and had more invasive tumors

10 (29%) of the 35 women with LUS tumors were confirmed to have Lynch syndrome or were strongly suspected to have Lynch syndrome on the basis of tissue-based molecular assays
KNOWN FACTS ABOUT ENDOMETRIAL CARCINOMA IN WOMEN WITH LYNCH SYNDROME

- **IS THE MOST COMMONLY OCCURRING TUMOR IN HNPCC FEMALE MUTATION CARRIERS**

- **IN ABOUT 50% OF WOMEN WITH HNPCC IS THE FIRST CANCER TO DEVELOP**

- **HAS AN EARLIER AGE OF ONSET WHEN COMPARED WITH SPORADIC ENDOMETRIAL CARCINOMA**

- **IS FREQUENTLY CENTERED IN THE LOWER UTERINE SEGMENT**

- **MAY SHOW A SYNCHRONOUS OVARIAN CARCINOMA**

- **ITS HISTOLOGIC FEATURES AND BEHAVIOUR ARE NOT AS WELL KNOWN AS THOSE OF HNPCC-RELATED COLORECTAL CARCINOMA**
Lynch Syndrome-Related Endometrial Carcinomas Show a High Frequency of Nonendometrioid Types and of High FIGO Grade Endometrioid Types.

Carcangiu ML, Radice P, Casalini P, Bertario L, Merola M, Sala P.
Int J Surg Pathol. 2010; 18:21
LS-RELATED ENDOMETRIAL CARCINOMA

Endometrial carcinoma in 23 patients with proved MMR mutation (mean age 42.6 ys)

EVALUATED FOR :
HISTOLOGIC TYPE
HISTOLOGIC GRADE
VASCULAR INVASION
NON NEOPLASTIC ENDOMETRIUM
STAGE
SURVIVAL

Carcangiu ML, Radice P, Casalini P
ENDOMETRIOID: 13 (56.5%)

NON-ENDOMETRIOID: 10 (43.4%)
### Comparison of the Frequency of Histologic Types and FIGO Grades of Endometrial Cancers in Lynch Syndrome Patients and Controls

<table>
<thead>
<tr>
<th>Histologic Type</th>
<th>Lynch Syndrome-Related EC (23)</th>
<th>Controls (46)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endometrioid</strong></td>
<td>13 (56.5%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>44 (95.6%)&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>FIGO Grade I</td>
<td>3 (23.0%)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>20 (45.4%)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>FIGO Grade II</td>
<td>4 (30.7%)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>19 (43.1%)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>FIGO Grade III</td>
<td>6 (46.1%)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>5 (11.3%)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Non-Endometrioid</strong></td>
<td>10 (43.4%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2 (4.3%)&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Clear Cell</td>
<td>5 (50.0%)</td>
<td>0</td>
</tr>
<tr>
<td>Serous</td>
<td>2 (20.0%)</td>
<td>1</td>
</tr>
<tr>
<td>MMMT</td>
<td>2 (20.0%)</td>
<td>0</td>
</tr>
<tr>
<td>Neuroendocrine</td>
<td>1 (10.0%)</td>
<td>1</td>
</tr>
</tbody>
</table>

**EC**: endometrial cancer

<sup>1</sup>: P<0.0001 by Fisher’s exact test
<sup>2</sup>: P = 0.0368 by Chi-square test

Lymphovascular invasion: 45.5%
Inflammatory infiltrate: 50%
Endometrial glandular hyperplasia 52.2%

Endometrial Intraepithelial carcinoma (EIC): 6.8%
HISTOLOGY AND GENE MUTATION IN LYNCH SYNDROME-RELATED ENDOMETRIAL CANCERS

<table>
<thead>
<tr>
<th>HISTOLOGIC TYPE</th>
<th>MLH1</th>
<th>MSH2</th>
<th>MLH1:MSH2</th>
<th>TOTAL(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDO-METRIOID</td>
<td>5 (38.4%)</td>
<td>7 (53.8%)</td>
<td>1 (7.6%)</td>
<td>13</td>
</tr>
<tr>
<td>NON-ENDOMETRIOID</td>
<td>2 (20%)</td>
<td>8° (80%)</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>TOTAL</td>
<td>7</td>
<td>15</td>
<td>1</td>
<td>23</td>
</tr>
</tbody>
</table>

°: INCLUDING 6 CASES WITH COMBINED NEEC AND ECC HISTOLOGY

### STAGE DISTRIBUTION OF LYNCH SYNDROME-RELATED ENDOMETRIAL CANCERS AND CONTROLS

<table>
<thead>
<tr>
<th>STAGE</th>
<th>LYNCH SYNDROME-RELATED EC</th>
<th>CONTROL EC</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>0</td>
<td>10(21.7%)</td>
</tr>
<tr>
<td>IB</td>
<td>13(56.5%)</td>
<td>24(52.1%)</td>
</tr>
<tr>
<td>IC</td>
<td>4(17.3%)</td>
<td>3(6.5%)</td>
</tr>
<tr>
<td>IIB</td>
<td>3(13.0%)</td>
<td>5(10.8%)</td>
</tr>
<tr>
<td>IIIA</td>
<td>1(4.3%)</td>
<td>3(6.5%)</td>
</tr>
<tr>
<td>IIIC</td>
<td>2(8.7%)</td>
<td>1(2.1%)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>23</td>
<td>46</td>
</tr>
</tbody>
</table>

EC: endometrial cancer

## SURVIVAL OF PATIENTS WITH LYNCH SYNDROME-RELATED ENDOMETRIAL CANCER ACCORDING TO FIGO STAGE

<table>
<thead>
<tr>
<th>STAGE</th>
<th>A&amp;W</th>
<th>DOD</th>
<th>DOC</th>
<th>TOT</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>13(76.4%)</td>
<td>2(11.7%)</td>
<td>2(11.7%)</td>
<td>17</td>
</tr>
<tr>
<td>II</td>
<td>2(66.6%)</td>
<td>1(33.3%)</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>III</td>
<td>0</td>
<td>2(66.6%)</td>
<td>1(33.3%)*</td>
<td>3</td>
</tr>
<tr>
<td>TOTAL</td>
<td>15(65.2%)</td>
<td>5(21.7%)</td>
<td>3 (13.0%)</td>
<td>23</td>
</tr>
</tbody>
</table>

* Patient ç recurrent endometrial carcinoma
## Survival of Patients with Lynch Syndrome-Related Endometrial Cancer According to Histology

<table>
<thead>
<tr>
<th></th>
<th>Endometrioid</th>
<th>Non-Endometrioid</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A&amp;W</td>
<td>10 (76.9 %)</td>
<td>5 (50.0 %)</td>
<td>15 (65.2 %)</td>
</tr>
<tr>
<td>DOD</td>
<td>1 (7.6 %)</td>
<td>4 (40.0 %)</td>
<td>5 (21.7 %)</td>
</tr>
<tr>
<td>DOC</td>
<td>2+° (15.3 %)</td>
<td>1* (10.0 %)</td>
<td>3 (13.0 %)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>13</td>
<td>10</td>
<td>23</td>
</tr>
</tbody>
</table>

*Dead of colonic cancer (patient ç recurrent endometrial carcinoma)
+Dead of pancreatic cancer
°Dead of colonic cancer
## NEOPLASMS AT OTHER SITES ASSOCIATED WITH LYNCH SYNDROME-
RELATED ENDOMETRIAL CANCERS ACCORDING TO GENE MUTATION

<table>
<thead>
<tr>
<th></th>
<th>ALL CASES</th>
<th>MLH1</th>
<th>MSH2</th>
<th>MLH1/ MSH2</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLORECTUM</td>
<td>12</td>
<td>2</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>SKIN</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STOMACH</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>BREAST</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PANCREAS</td>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>OVARY</td>
<td>2+</td>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>URINARY TRACT</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>22</strong></td>
<td><strong>4</strong></td>
<td><strong>16</strong></td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>

+ (8.6%) BOTH CLEAR CELL CARCINOMAS
CONCLUSIONS

1) THE FREQUENCY OF NON ENDOMETRIOID CARCINOMA (PARTICULARLY CLEAR CELL CARCINOMA, PURE OR ADMIXED WITH ENDOMETRIOID CARCINOMA) IS HIGHER AMONG UTERINE TUMORS IN HNPCC WOMEN THAN AMONG WOMEN WITH SPORADIC UTERINE TUMORS, DESPITE THE TENDENCY OF HNPCC-RELATED TUMORS TO OCCUR IN YOUNGER PATIENTS, AN AGE GROUP IN WHICH NON ENDOMETRIOID CARCINOMAS ARE DISTINCTLY RARE;

2) PURE ENDOMETRIOID CARCINOMAS OCCURRING IN HNPCC WOMEN TEND TO BE OF HIGHER FIGO GRADE THAN THEIR SPORADIC COUNTERPARTS;
3) BOTH ENDOMETRIOID AND NON ENDOMETRIOID CARCINOMAS IN HNPCC WOMEN SHOW FIGO STAGE DISTRIBUTIONS SIMILAR TO THOSE SEEN IN THE CORRESPONDING SPORADIC CASES

4) AS A GROUP, HNPCC-RELATED UTERINE CARCINOMA IS MORE LIKELY TO EXHIBIT MICROSCOPICALLY AGGRESSIVE FEATURES THAN ITS SPORADIC COUNTERPART (GREATER NUMBER OF CASES WITH A NON ENDOMETRIOID COMPONENT AND HIGHER FIGO GRADES AMONG THE PURE ENDOMETRIOID CARCINOMAS), BUT FROM THIS STUDY IT DOES NOT EMERGE AS A DISTINCT PATHOLOGIC SUBTYPE OF UTERINE CARCINOMA.
More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon. 

van den Bos M, van den Hoven M, Jongejan E, et al. 

6 CASES

<table>
<thead>
<tr>
<th></th>
<th>HNPCC-RELATED CARCINOMA</th>
<th>CONTROLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poorly differentiated</td>
<td>83%</td>
<td>27%</td>
</tr>
<tr>
<td>Crohn-like lymphoid reaction</td>
<td>100%</td>
<td>13%</td>
</tr>
<tr>
<td>Lymphangioinvasive growth</td>
<td>67%</td>
<td>0</td>
</tr>
<tr>
<td>High number of tumor-infiltrating lymphocytes</td>
<td>100%</td>
<td>36%</td>
</tr>
</tbody>
</table>
### Pathologic features of endometrial carcinoma associated with HNPCC

Broaddus RR et al.  
Cancer. 2006;106:87-94.

<table>
<thead>
<tr>
<th></th>
<th>HNPCC</th>
<th>SPORADIC CA &lt; 50 YS</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. OF CASES</td>
<td>50</td>
<td>42</td>
</tr>
<tr>
<td>MEAN AGE</td>
<td>46.8%</td>
<td>39.9%</td>
</tr>
<tr>
<td>ENDOMETRIOID TYPE</td>
<td><strong>86.0%</strong></td>
<td><strong>97.6%</strong></td>
</tr>
<tr>
<td>GRADE I</td>
<td>44.2%</td>
<td>39.0%</td>
</tr>
<tr>
<td>GRADE II</td>
<td>39.5%</td>
<td>51.2%</td>
</tr>
<tr>
<td>GRADE III</td>
<td>16.3%</td>
<td>9.8%</td>
</tr>
<tr>
<td>STAGE I</td>
<td>78.0%</td>
<td>66.7%</td>
</tr>
<tr>
<td>STAGE II</td>
<td>10.0%</td>
<td>7.1%</td>
</tr>
<tr>
<td>STAGE III/IV</td>
<td>12.0%</td>
<td>26.2%</td>
</tr>
<tr>
<td>MYOMETRIAL INV &gt;50%</td>
<td><strong>26.0%</strong></td>
<td><strong>23.8%</strong></td>
</tr>
<tr>
<td>LYMPH/VASC INVASION</td>
<td>24.0%</td>
<td>40.5%</td>
</tr>
</tbody>
</table>
35 (3.5%) of 1,009 women with endometrial cancer had endometrial carcinoma of the LUS.

LUS patients were younger, had higher stage tumors, and had more invasive tumors.

10 (29%) of the 35 women with LUS tumors were confirmed to have Lynch syndrome or were strongly suspected to have Lynch syndrome on the basis of tissue-based molecular assays.
Carcinoma of the Lower Uterine Segment: A Newly Described Association With Lynch Syndrome
Westin, S. N. et al.
Journal of Clinical Oncology, 26, 2008:5965-5971

<table>
<thead>
<tr>
<th></th>
<th>LUS WITH LS</th>
<th>LUS WITHOUT LS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDOMETRIOID</td>
<td>6 (60.0%)</td>
<td>21 (84.0%)</td>
</tr>
<tr>
<td>NONENDOMETRIOID</td>
<td>4 (40.0%)</td>
<td>4 (16.0%)</td>
</tr>
</tbody>
</table>

- THE IHC ABNORMAL GROUP SHOWED MORE FREQUENT:
  - tumor infiltrating lymphocytes
  - dedifferentiated EC
  - more tumors centered in the lower uterine segment
  - more frequent synchronous clear cell carcinomas of the ovary
Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer.

**Boks DE et al.**


**Figure 1** – Cumulative survival of patients with HNPCC-associated endometrial carcinoma and age- and stage-matched controls with endometrial carcinoma.
Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer.

**Boks DE et al.**


<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Study group 50 (%)</th>
<th>Control group 100 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (range)</td>
<td>49.9 (31–69)</td>
<td>53.7 (30–72)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>11 (22)</td>
<td>22 (22)</td>
</tr>
<tr>
<td>IB</td>
<td>21 (42)</td>
<td>42 (42)</td>
</tr>
<tr>
<td>IC</td>
<td>7 (14)</td>
<td>14 (14)</td>
</tr>
<tr>
<td>IIIA</td>
<td>9 (18)</td>
<td>18 (18)</td>
</tr>
<tr>
<td>IIIC</td>
<td>2 (4)</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid/adenocarcinoma</td>
<td>46 (92)</td>
<td>88 (88)</td>
</tr>
<tr>
<td>Papillary/serous carcinoma</td>
<td>1 (2)</td>
<td>7 (7)</td>
</tr>
<tr>
<td>Clear-cell carcinoma</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (4)</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (2)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

1 Stage IA, IB, IC, IIIA AND IIIC. 2-t-test: \( p = 0.004 \)
OVARIAN CARCINOMA
CAUSES OF HEREDITARY SUSCEPTIBILITY TO OVARIAN CANCER

BRCA1: 70%
BRCA2: 20%
Others (Li Fraumeni S., Cowden S., Peutz Jeghers S., Gorlin S. Ataxia Telangiectasia)

2% MMR (MSH1, MLH2)

8-10% Sporadic
90% Hereditary
LIFETIME RISK OF CANCER REPORTED IN FAMILIES WITH AN IDENTIFIED MISMATCH REPAIR MUTATION

- Colorectal cancer (men): 28–75%
- Colorectal cancer (women): 24–52%
- **Endometrial cancer:** 27–71% [2.3%]
- **Ovarian cancer:** 3.6 –13% [1.8%]
- Gastric cancer: 2–13%
- Urinary tract cancer: 1–12%
- Brain tumour: 1–4%
- Bile duct/gallbladder cancer: 2%
- Small-bowel cancer: 4–7%

Mean age at diagnosis:

HNPCC-ovarian cancer: 41-49 yrs
Sporadic ovarian cancer: 60-65 yrs
A consecutive series of 128 tumors unselected for age at diagnosis

Loss of MMR protein expression was identified in 3 ovarian cancers (2%), all MSI-H.

Germline mutation was identified in 2 cases: **MLH1** (mucinous-endometrioid) and **MSH6** (clear cell)
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.

Domanska K, Malander S, Måsbäck A, Nilbert M.

Int J Gynecol Cancer. 2007;17:789-93.

98 invasive epithelial ovarian cancers that developed before 40 years from the Swedish Cancer Registry.

- Loss of expression of:
  - MLH1/PMS2 in two cases
  - MSH2/MSH6 in one case
  - MSH6 only in three tumors

- A microsatellite instability-high phenotype was verified in five of the six tumors.
Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.

Jensen KC, Mariappan MR, Putcha GV et al.  

- 52 ovarian surface epithelial carcinomas in patients < =50 ys

- Defects in MMR in 5 of 52 (10%)

- MMR inactivation in 17% of ovarian clear cell carcinomas including 4 with synchronous endometrial carcinomas
79 ovarian cancer patients who were members of HNPCC families
– Mean age at diagnosis of ovarian cancer: 42.7 ys.
– Nonepithelial tumors: 6.4% of the cancers
– Borderline tumors: 4.1% of the epithelial cancers.
– HISTOLOGIC TYPES OF INVASIVE CARCINOMA: serous (30%), mucinous (7%), endometrioid (13%), clear cell (7%), other (4%)
– Most malignant epithelial cancers were well or moderately differentiated
– 85% were FIGO stage I or II at diagnosis
– Synchronous endometrial cancer was reported in 21.5% of the cases
Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.

Ketabi Z, Bartuma K, Bernstein I, Malander S, Grönberg H, Björck E, Holck S, Nilbert M.

Gynecol Oncol. 2011 Mar 7. [Epub ahead of print]

HNPPCC-register, Department of Gastroenterology, Hvidovre University Hospital, Faculty of Health Sciences, Copenhagen University, Denmark.
- 63 epithelial ovarian cancers
- mean age 48 (range 30-79 years of age)
- 47% FIGO stage I
- MSH2:49%, MSH6:33%, MLH1:17%. Immunohistochemical loss of the corresponding MMR protein was demonstrated in 33/36 (92%) tumors analyzed.
- The ovarian cancer was the sentinel tumor in 12 patients
- Synchronous endometrial carcinoma: 4 patients

- Histologic type:
- endometrioid :35%; clear cell :17%; serous: 28%; mucinous:5%; undifferentiated:15%
Ovarian tumors in Lynch syndrome: genotype-phenotype correlation.

Ryan P et al. Poster 1124, USCAP 2011

• 15 ovarian cancers identified retrospectively from the cancer registries in Toronto, Vancouver and Montreal
• Mean age: 42.8 yrs (range 31-53 yrs, 1 > 50 years old)
• MSH2 mutations: 12
• MLH1 mutations: 3
• Ovarian cancer was the sentinel tumor in 12 patients
• Colonic cancer was the sentinel tumor in 3 patients
• Stage I: 7 cases (4 with synchronous endometrial carcinoma)

• Histologic type:
  • Mixed: 6, Endometrioid: 3, Clear cell: 2, Serous: 2, Mucinous: 1, Squamous cell: 1
OVARIAN CA IN MMR MUTATION CARRIERS

• ~2% OF ALL OVARIAN CANCERS

• ~10% OF ALL HEREDITARY OVARIAN CANCERS

• MORE FREQUENT IN WOMEN WITH MUTATIONS IN MSH2 AND MSH6 GENES

• EARLY AGE ONSET

• MOSTLY EPITHELIAL

• MODERATELY OR WELL DIFFERENTIATED

• FREQUENTLY CLEAR CELL, MUCINOUS AND ENDOMETRIOID TYPE

• MOSTLY LOW STAGE

• ARE MORE LIKELY TO HAVE A SYNCHRONOUS ENDOMETRIAL CANCER

• SURVIVAL RATE SIMILAR TO THAT OF SPORADIC OVARIAN CANCER
• 26 patients with OC from the Dutch HNPCC Registry.  
• Control group (52 cases) matched for age, stage and year of diagnosis derived from the population-based Eindhoven Cancer Registry.

• The mean age at diagnosis of OC-HNPCC was significantly lower than the age of sporadic OC (49.5 vs 60.9 years).

• In comparison to sporadic OC significantly more OC-HNPCC tumors were diagnosed at an early stage.

• The distribution of histologic types was not significantly different between the study and control group.
– The **survival rate was not significantly different** between patients with OC-HNPCC and the age- and stage-matched controls.

– The cumulative 5-year-survival rates were 64.2 and 58.1% respectively.
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds

Eli Marie Grindedal, Laura Renkonen-Sinisalo, Hans Vasen, Gareth Evans, Paola Sala, Ignacio Blanco, Jacek Gronwald, Jaran Apold, Diana M Eccles, Ángel Alonso Sánchez, Julian Sampson, Heikki J Järvinen, Lucio Bertario, Gillian C Crawford, Astrid Tenden Stormorken, Lovise Maehle, Pal Moller

- 144 women
- 81.5% FIGO stage I or II

- 10-year specific survival independent of staging: 80.6% vs. <40% survival reported both in population based series and in BRCA-mutation carriers

- Disease specific 30 years survival: 71.5%

- Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR-mutation carriers
Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier.

High risk for neoplastic transformation of endometriosis in a carrier of Lynch syndrome.
Nyiraneza C, Marbaix E, Smets M, Galant C, Sempoux C, Dahan K.
Fam Cancer. 2010;9:383-7

Report of a case of a healthy woman carrying a germline mutation in MLH1 gene with endometrial intra-epithelial neoplasia and ovarian endometriotic lesions exhibiting a loss of MLH1 protein expression
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome


Retrospective study of 315 pts
Hysterectomy done in 61
Salpingo-oophorectomy done in 47

• In operated pts no endometrial, ovarian or peritoneal cancer
• In unoperated pts 69 (33%) cases of endometrial cancer and 12 (5%) cases of ovarian cancer
• Prevented fraction 100%
Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome.

Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM, Chang GJ, Lu KH.

Obstet Gynecol. 2010;115(2 Pt 2):432-4

- 44-year-old woman who underwent hysterectomy with BSO for benign disease. She presented 12 years later with a pelvic mass and was diagnosed with a high-grade serous primary peritoneal cancer. Genetic testing showed a mutation in the MSH2 DNA mismatch repair gene.

- 58-year-old woman who had a hysterectomy and BSO for endometrial cancer. She developed a high-grade serous primary peritoneal cancer 8 years later and was found to have a mutation in the PMS2 DNA mismatch repair gene.